Barinthus Biotherapeutics (BRNS) Receivables - Other (2020 - 2025)
Barinthus Biotherapeutics (BRNS) has disclosed Receivables - Other for 6 consecutive years, with $4.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Other fell 14.25% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Sep 2025, down 14.25%, and an annual FY2024 reading of $7.1 million, up 45.46% over the prior year.
- Receivables - Other was $4.6 million for Q3 2025 at Barinthus Biotherapeutics, up from $4.5 million in the prior quarter.
- Across five years, Receivables - Other topped out at $7.1 million in Q4 2024 and bottomed at $349000.0 in Q2 2023.
- Average Receivables - Other over 5 years is $4.4 million, with a median of $4.6 million recorded in 2021.
- The sharpest move saw Receivables - Other tumbled 93.31% in 2023, then soared 1195.99% in 2024.
- Year by year, Receivables - Other stood at $6.2 million in 2021, then dropped by 27.1% to $4.5 million in 2022, then increased by 8.08% to $4.9 million in 2023, then soared by 45.46% to $7.1 million in 2024, then tumbled by 35.1% to $4.6 million in 2025.
- Business Quant data shows Receivables - Other for BRNS at $4.6 million in Q3 2025, $4.5 million in Q2 2025, and $3.0 million in Q1 2025.